Lotte Biologics Signed Agreement With Alvotech
The partnership brings new antibody biosimilar production to the Lotte Biologics facility in Syracuse.
Updated on Oct. 7, 2026 in Manufacturing
Live Poll
Do you believe pharmaceutical manufacturing partnerships ultimately lead to more affordable medicines for patients?
Lotte Biologics has secured a manufacturing agreement with Alvotech to produce antibody biosimilar drug substances. The deal centers on production at the Lotte Biologics plant located in Syracuse.
Why it matters
The collaboration enables Alvotech to maintain a more flexible response to shifting global market demands. Both companies intend to expand this relationship further in the coming years.
The Syracuse facility operates with 40,000 liters of bioreactor capacity. This manufacturing support is projected to help Alvotech meet its pipeline demand for the next ten years.
The players
Lotte Biologics
This company is a global contract development and manufacturing organization that maintains a major facility in Syracuse.
Alvotech
This biotechnology company focuses on the development and manufacturing of biosimilar medicines for patients worldwide.
The details
Lotte Biologics will leverage its in-house process development and quality control capabilities to manage the production of the drug substances. The facility recently cleared a US Food and Drug Administration inspection with zero observations.
Timeline
October 6, 2026: The companies signed the agreement at CPHI Milan 2026.
October 6-8, 2026: CPHI Milan 2026 was held in Italy.
Market Landscape
The deal reflects the increasing integration of global biosimilar supply chains as manufacturers seek to optimize production footprints. This partnership positions the companies to compete more effectively against established firms by leveraging specialized local manufacturing infrastructure.
Local operations in Syracuse are bolstered by the addition of this long-term biosimilar production contract. The increased utilization of the facility supports regional employment and highlights the site's regulatory compliance standards.
The takeaway
This agreement highlights the strategic importance of high-capacity, regulatory-approved facilities in the competitive biosimilar market. Companies increasingly rely on partnerships to balance long-term pipeline demands with the need for flexible manufacturing output.
Further reading
For more on local industrial developments, visit the Manufacturing section.
Live Poll
Do you believe pharmaceutical manufacturing partnerships ultimately lead to more affordable medicines for patients?
